Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00563732|
Recruitment Status : Completed
First Posted : November 26, 2007
Last Update Posted : September 9, 2008
Primary: To evaluate the effects of multiple doses of lecozotan SR on the PK profile of a single dose of digoxin in healthy adult subjects.
Secondary: To assess the safety and tolerability of the coadministration of lecozotan SR and digoxin.
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease||Drug: Lecozotan||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Lecozotan SR and a Single Oral Dose of Digoxin When Administered Orally to Healthy Adult Subjects|
|Study Start Date :||December 2007|
|Actual Primary Completion Date :||September 2008|
|Actual Study Completion Date :||September 2008|
- Evaluation of the effects of multiple doses of lecozotan SR on the PK profile of a single dose of digoxin in healthy adult subjects
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00563732
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|